The Company plans on becoming a significant transdisciplinary biomedical/biotechnology company involved in the discovery, development, acquisition and commercialization of a broad range of biotechnology, and biomedical technologies as well as nutraceutical and molecular diagnostic technologies to improve human health.
We intend to develop, manufacture and sell directly or indirectly through collaborative partners, the following types of products:
PRODUCT/R&D PHASE/DESCRIPTION VivaThermic Vials / Phase III / Centrifugable and autoclavable vials for cryopreservation
Cryopsy / Phase I / Device that rapidly freezes tissue specimens
VivaSight / Phase II / Digital PhotoRefractor for children's vision screening
VivAuris / Phase II / nDevice for middle ear redness detection
VivaGlobin / Phase II / Device for anemia and Cutaneous hemoglobin detection
VivaBlend / Phase III / Concentrated phytochemical/ antioxidant extract supplement
VivaGastroProtect / Phase I / Fruits and vegetables extract for the protection of digestive system
VivaCrop /Phase I / Vegetation health monitor
Clinical Sensor (CBS)/ Phase I / In vitro diagnostic device used at the point of care
SLICES / Phase II /MRI enhancement software
We also plan to continue to offer contract research and development services in molecular biology, device engineering and other areas. We commenced providing contract research and development services in the first quarter of 2008. During the first quarter 2009, we commenced sales of our VivaThermic vials and we commenced sales of VivaBlend in the second quarter of 2009. In December 2009, we entered into a license agreement with Regeneca International, Inc. (“Regeneca”) for VivaBoost whereby Regeneca obtained exclusive worldwide distribution rights in the direct-to-consumer market and has committed to purchase $5,000,000 of product over a thirty-six month period. ....